

IVMB0453

| Product Information | | | | | | |
|------------------------|------------------|--|---------|------------------|---------------------|--|
| Product SKU: | IVMB0453 | Clone: | MDX-010 | Target: | CTLA-4 | |
| Size: | 100 µg | | | Isotype : | Human lgG1ĸ | |
| | | | | | | |
| Additional Information | | | | | | |
| Reactivity: | Human | | | Host Species | s : Human | |
| Antibody Type | e: Biosimilar Re | Biosimilar Recombinant Human Monoclonal Antibody | | Expression H | lost: HEK-293 Cells | |
| | | | | | | |

Immunogen Information

| Background: | Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) is a protein receptor that serves as |
|------------------------|---|
| | an immune checkpoint and down-regulates the immune system. CTLA-4 is constitutively |
| | expressed in regulatory T cells but is only upregulated in conventional T cells following |
| | activation. Many cancers, including Melanoma, are associated with CTLA-4 upregulation |
| | because the body's ability to recognize and destroy cancer cells is hampered by an inhibitory |
| | mechanism. Ipilimumab targets CTLA-4 and works by turning off this inhibitory mechanism |
| | and, thus, enhances the body's own immune response against cancer cells." ² Emerging |
| | research suggests that combined blockade of PD-1 and CTLA-4, with Nivolumab and |
| | Ipilimumab respectively, could produce greater antitumor activity than blockade of either |
| | pathway alone. ¹ This cost-effective, research-grade Anti-Human CTLA-4 (Ipilimumab) |
| | utilizes the same variable regions from the therapeutic antibody Ipilimumab making it ideal |
| | for research projects. |
| Product Concentration: | 0.5 mg/ml |
| Applications : | ELISA |
| Synonyms: | CD; GSE; GRD4; ALPS5; CD152; CTLA-4; IDDM12; CELIAC3 |
| Antigen Distribution: | CTLA4 is constitutively expressed in regulatory T cells. |
| Immunogen: | Human CTLA-4 |



| Formulation: | This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) |
|---------------------|--|
| | PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. |
| Specificity: | This non-therapeutic biosimilar antibody uses the same variable region sequence as the |
| | therapeutic antibody Ipilimumab. Ipilimumab binds to Human CTLA-4. This product is for |
| | research use only. |
| Pathogen Testing: | - |
| | |
| Storage & Handling: | This biotinylated antibody is stable when stored at 2-8°C.Do not freeze. |